NO20054221D0 - Anti-angiogene og anti-tumorale egenskaper til beta og gamma sekretaseinhibitorer - Google Patents

Anti-angiogene og anti-tumorale egenskaper til beta og gamma sekretaseinhibitorer

Info

Publication number
NO20054221D0
NO20054221D0 NO20054221A NO20054221A NO20054221D0 NO 20054221 D0 NO20054221 D0 NO 20054221D0 NO 20054221 A NO20054221 A NO 20054221A NO 20054221 A NO20054221 A NO 20054221A NO 20054221 D0 NO20054221 D0 NO 20054221D0
Authority
NO
Norway
Prior art keywords
angiogenic
beta
gamma secretase
secretase inhibitors
tumor properties
Prior art date
Application number
NO20054221A
Other languages
English (en)
Other versions
NO20054221L (no
Inventor
Daniel Paris
Michael J Mullan
Original Assignee
Roskamp Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roskamp Res Llc filed Critical Roskamp Res Llc
Publication of NO20054221D0 publication Critical patent/NO20054221D0/no
Publication of NO20054221L publication Critical patent/NO20054221L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20054221A 2003-02-18 2005-09-12 Anti-angiogene og anti-tumorale egenskaper til beta og gamma sekretaseinhibitorer NO20054221L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31995403P 2003-02-18 2003-02-18
PCT/US2004/004494 WO2004073630A2 (en) 2003-02-18 2004-02-18 Anti-angiogenic and anti-tumoral properties of beta and gamma secretase inhibitors

Publications (2)

Publication Number Publication Date
NO20054221D0 true NO20054221D0 (no) 2005-09-12
NO20054221L NO20054221L (no) 2005-11-11

Family

ID=32907558

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054221A NO20054221L (no) 2003-02-18 2005-09-12 Anti-angiogene og anti-tumorale egenskaper til beta og gamma sekretaseinhibitorer

Country Status (9)

Country Link
US (1) US20040229816A1 (no)
EP (1) EP1596878A4 (no)
JP (1) JP2006517979A (no)
CN (1) CN1777436A (no)
AU (1) AU2004212965A1 (no)
BR (1) BRPI0407597A (no)
CA (1) CA2516259A1 (no)
NO (1) NO20054221L (no)
WO (1) WO2004073630A2 (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1671129A1 (en) * 2003-07-21 2006-06-21 Angiogenetics Sweden AB Compounds and methods for promoting angiogenesis by using a gamma-secretase inhibitor or inhibiting the gamma-secretase pathway
EP1666068A4 (en) * 2003-09-24 2010-08-04 Santen Pharmaceutical Co Ltd REMEDY FOR EYE DISEASES ACCOMPANIED BY OPTICAL NERVE INJURIES
NZ555216A (en) * 2004-11-10 2010-05-28 Hubrecht Lab Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
WO2006051405A2 (en) * 2004-11-12 2006-05-18 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
WO2006123183A2 (en) * 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Sulphone derivatives for treatment of cancer
US20090215775A1 (en) * 2005-05-17 2009-08-27 Huw David Lewis Sulphonamido-Substituted Cyclohexyl Sulphones for Treatment of Cancer
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
US8242103B2 (en) 2005-05-19 2012-08-14 Merck Sharp & Dohme Limited Sulphamides for treatment of cancer
CA2644136A1 (en) * 2006-02-27 2007-09-07 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
EP2011513B1 (en) 2006-04-25 2016-10-19 The University of Tokyo Therapeutic agents for alzheimer's disease and cancer
US8110557B2 (en) * 2006-07-05 2012-02-07 The Trustees Of The University Of Pennsylvania Gamma secretase inhibitor for treatment of herpesvirus infection
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2008061673A2 (en) * 2006-11-24 2008-05-29 Synthon B.V. Drug discovery for cancer
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
GB0706658D0 (en) * 2007-04-05 2007-05-16 Imp Innovations Ltd Breast cancer methods, medicaments and agents
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
KR100881747B1 (ko) * 2007-06-08 2009-02-06 한양대학교 산학협력단 호흡기 염증 질환중 기도 염증, 점막단백의 과다 생성, 및 기도 과민 증상을 예방 및 치료하기 위한 약학적 조성물
EP2044951A1 (en) * 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
US8377886B2 (en) * 2007-09-14 2013-02-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
WO2009100218A2 (en) * 2008-02-05 2009-08-13 Uab Research Foundation Kruppel-like transcription factor klf4/gklf and uses thereof
WO2010063718A1 (en) * 2008-12-02 2010-06-10 ETH Zürich Screening assay for metabolic disease therapeuticals
US20110059114A1 (en) * 2009-08-05 2011-03-10 Duke University Compositions and Methods for the Treatment of Radioresistant Glioma Stem Cells
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
CN104987328A (zh) * 2012-05-23 2015-10-21 复旦大学 7-氧、硫或氮杂取代香豆素及其衍生物和用途
CA2899507A1 (en) * 2013-03-14 2014-09-25 The Regents Of The University Of California In vitro production of medial ganglionic eminence precursor cells
US9558394B2 (en) * 2014-03-10 2017-01-31 Case Western Reserve University Histogram of hosoya index (HoH) features for quantitative histomorphometry
KR20180091024A (ko) * 2015-12-02 2018-08-14 클리어라이트 다이어그노스틱스 엘엘씨 암의 검출 및 모니터링을 위해 종양 조직 시료를 준비하고 분석하는 방법
CN107349414A (zh) * 2016-05-10 2017-11-17 北京市神经外科研究所 蛋白功能抑制剂dapt在制备治疗肿瘤的药物中的用途
EP4520828A3 (en) * 2016-11-15 2025-07-09 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
US11739326B2 (en) 2017-11-14 2023-08-29 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
US20210309726A1 (en) * 2018-05-21 2021-10-07 New York University Treatment of melanoma brain metastasis by inhibition of amyloid precursor protein cleavage
KR102130281B1 (ko) * 2020-06-19 2020-07-08 성균관대학교산학협력단 감마 세크레타제 억제제를 포함하는 인간거대세포바이러스 감염 질환 예방 또는 치료용 약학적 조성물, 및 감마 세크레타제를 이용한 인간거대세포바이러스 감염 질환 치료제의 스크리닝 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008710D0 (en) * 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic compounds
US20020151487A1 (en) * 2000-08-31 2002-10-17 Loyola University Chicago Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway
US6436629B1 (en) * 2000-10-27 2002-08-20 The Regents Of The University Of California Modulating angiogenesis
WO2005074633A2 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer

Also Published As

Publication number Publication date
NO20054221L (no) 2005-11-11
JP2006517979A (ja) 2006-08-03
CN1777436A (zh) 2006-05-24
US20040229816A1 (en) 2004-11-18
WO2004073630A2 (en) 2004-09-02
BRPI0407597A (pt) 2006-02-21
AU2004212965A1 (en) 2004-09-02
CA2516259A1 (en) 2004-09-02
EP1596878A2 (en) 2005-11-23
WO2004073630A3 (en) 2005-04-28
EP1596878A4 (en) 2008-05-28

Similar Documents

Publication Publication Date Title
NO20054221D0 (no) Anti-angiogene og anti-tumorale egenskaper til beta og gamma sekretaseinhibitorer
DK1592686T3 (da) Gyrase-inhibitorer og anvendelser deraf
ATE515495T1 (de) Gamma sekretase inhibitoren
DK1997809T3 (da) P38-inhibitorer og fremgangsmåder til anvendelse deraf
IS2675B (is) P38-hindrar og aðferðir til notkunar þeirra
NL350092I2 (nl) Combinatie van bixafen en fluoxastrobine
NO20055837D0 (no) Immunsupprimerende forbindelser og sammensetninger
IL174270A0 (en) Novel gamma secretase inhibitors
DE602004015415D1 (de) Malonamidderivate als gamma-secretaseinhibitoren
PL371735A1 (en) Gamma secretase inhibitors
NO20044915L (no) C-aryl-glukosid SGLT2 inhibitorer og metode
ATE396990T1 (de) Makrocyclische inhibitoren der beta-sekretase
ZA200507170B (en) Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
IS7966A (is) Pyrazól og aðferðir við að búa þau til og notkun þeirra
DK1628530T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis
DK1711470T3 (da) Malonamidderivater der blokerer aktiviteten af gamma-sekretase
NO20044148L (no) Sammensetning og fremgangsmate for bronnrensing
DK1664746T3 (da) Antioxidantsensor og fremgangsmåde
DK3144240T3 (da) Stabelbar pakning og fremgangsmåde til tilvejebringelse heraf
DK1539224T3 (da) Antimikrobielt præparat og fremgangsmåde til anvendelse
NO20055211D0 (no) Anti-fungale forbindelser og fremgangsmater for anvendelse
NO20054133D0 (no) Antineoplastiske kombinasjoner omfattende at rapamycin derivat og en aromatase inhibitor
EP1686981A4 (en) COMPOSITIONS AND METHODS FOR COMBINED RADIATION THERAPY AND CHEMOTHERAPY
DK1551805T3 (da) Substituerede gamma phenyl delta lactamer og dertil knyttede anvendelser
NO20054095D0 (no) Pyridyloksymetyl og benzioksazolazabicyklisk derivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application